Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. It offers XTANDI, an androgen receptor signaling inhibitor for the treatment of prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB); and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ transplant rejection. The company also provides Vesicare for OAB treatment; Eligard for prostate cancer treatment; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical collaboration agreement with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and Cytokinetics, Incorporated, as well as an agreement with BANDAI NAMCO Entertainment Inc. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. FARTCOIN price prediction: Third-party price targetRead our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
15:09, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price targetRead our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
13:12, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price targetRead our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:57, 22 January 2025
The year in review – a relentlessly dynamic 20242024 brought a gold boom, a dovish turn for central banks, endless macroeconomic upheaval, and so much more.
11:40, 21 January 2025